$RMTG

Regenerative Medical Technology Group (RMTG) launched a Natural Killer (NK) cell product line through its Cellgenic division, targeting international markets like Latin America and Southeast Asia. The move expands RMTG's cellular-technology portfolio and aims to meet growing demand for advanced cellular and immunology-related technologies. According to the company, the launch is a strategic step to leverage existing capabilities for near-term commercial opportunities.

Regenerative Medical Technology Group (OTC: RMTG) said its Cellgenic unit launched regulated commercial operations in Argentina after completing regulatory and operational milestones. The platform will support biologics distribution via licensed physicians, physician education with ISSCA, and regional expansion across Latin America. RMTG did not provide financial figures.

Regenerative Medical Technologies Group (OTC Pink: RMTG) said it launched the ISSCA AI Clinical Intelligence Platform, developed by its ISSCA education and innovation division. The platform is intended to help physicians interpret clinical data, organize workflows, and manage data complexity with clinical oversight. RMTG said ISSCA has relationships in 30+ countries and a mobile app, and it plans further AI and ecosystem integration.

Regenerative Medical Technologies Group (OTC: RMTG), via its ISSCA education unit, launched the ISSCA Mobile App, a physician-facing platform intended to digitize ISSCA’s education, certification, webinars, collaboration, and event access across its 30+ country network. The company says the app will support scalable engagement and serve as a foundation for future integration with “ISSCA AI.”